The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US ...

Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, ...

Merck on Thursday said its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, ...

Merck said the expected tariff charge primarily reflects levies between the U.S. and China, but does not account for Trump’s ...

Total Worldwide Sales Were $15.5 Billion, a Decrease of 2% From First Quarter 2024; Excluding the Impact of Foreign Exchange, ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...

Merck (MRK) stock trades flat as the company lowers earnings outlook amid tariff impact, even as its Q1 2025 results beat ...

Merck (NYSE:MRK) experienced a 2.98% share price increase over the past week, during which several key developments occurred. The company reaffirmed its 2025 financial guidance, despite a slight ...

Over the past five years, the stock has recorded a negative one-day return in 65% of cases, with a median decline of -2.4% ...

The interim results of a phase 3 trial of Merck’s pulmonary arterial hypertension (PAH) treatment Winrevair were so conclusive that the company not only halted the study for efficacy ...

Merck said today its first-quarter adjusted profit rose 7% as lower costs helped offset a 2% decline in sales, reflecting a ...